Global Mavacamten Capsules Market Size, Share & Trends Analysis Report By Indication (Obstructive Hypertrophic Cardiomyopathy, Non-Obstructive Hypertrophic Cardiomyopathy, Other Sarcomeric Cardiomyopathies), By Patient Type (Adult, Geriatric, Pediatric), By Line of Therapy (First-Line Disease-Specific Therapy, Second-Line Post-Septal Reduction, Add-On to Background Medical Therapy), By Dosage Strength (2.5 mg, 5 mg, 10 mg, 15 mg), By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Academic Medical Centers & Tertiary Care Hospitals, Specialized Cardiology Practices, Ambulatory Cardiology Clinics, Community Hospitals), and By Region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America) – Forecasts, 2026–2034

Table of Contents

1. Introduction
   1.1. Market Introduction
   1.2. Research Methodology
   1.3. Estimation Methodology
   1.4. Cardiovascular Precision Medicine Ecosystem Overview
   1.5. Market Classification & Scope
   1.6. Geographic Scope
   1.7. Study Years
2. Market Dynamics
   2.1. Drivers: Expanding Diagnosis of Hypertrophic Cardiomyopathy
   2.2. Drivers: Strong Clinical Evidence & Disease-Modifying Potential
   2.3. Restraints: REMS Program Requirements & Monitoring Burden
   2.4. Opportunities: Non-Obstructive HCM Label Expansion
   2.5. Trends: AI-Enabled Cardiac Imaging & Monitoring
3. Market Segmentation (2026–2034)
   3.1. By Indication
   3.2. By Patient Type
   3.3. By Line of Therapy
   3.4. By Dosage Strength
   3.5. By Distribution Channel
   3.6. By End-User
   3.7. By Region
4. Regional Overview
   4.1. North America
   4.2. Europe
   4.3. Asia Pacific
   4.4. Middle East & Africa
   4.5. Latin America
5. Competitive Analysis
   5.1. Market Structure & Competitive Benchmarking
   5.2. Revenue and Market Share Analysis
   5.3. Cardiac Myosin Inhibitor Pipeline Assessment
   5.4. Strategic Positioning & Product Differentiation
   5.5. Partnerships, Clinical Programs & Market Access Strategies
6. Clinical & Innovation Trends
   6.1. Disease-Modifying Therapy Evolution
   6.2. Non-Obstructive HCM Clinical Development
   6.3. AI-Based Echocardiographic Monitoring
   6.4. Genetic Testing & Precision Cardiology
   6.5. Next-Generation Cardiac Myosin Inhibitors
7. Regulatory & Reimbursement Landscape
   7.1. FDA Regulatory Framework
   7.2. REMS Program Requirements
   7.3. EMA Approval & European Access Pathways
   7.4. Reimbursement & Health Technology Assessment
   7.5. Specialty Pharmacy Distribution Framework
8. Market Research Findings & Conclusion
9. Disclaimer